CHRS Q4 2022 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M-38.2% YoY

Gross Profit

$31M68.7% margin

Operating Income

-$51M-113.5% margin

Net Income

-$59M-129.8% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$100M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$481M

Total Liabilities

$618M

Stockholders' Equity

-$137M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$73M	-38.2%
Gross Profit	$31M	$61M	-49.2%
Operating Income	-$51M	-$40M	-30.2%
Net Income	-$59M	-$46M	-28.7%

Revenue Segments

Product Revenue

$151M100%